ArticleJournal of biomedical research2018
Role of inflammasome regulation on immune modulators.
Article in Journal of biomedical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Host-Pathogen Interaction as a Driver of Cellular Senescence: Microbial Triggers and Host Response.International journal of molecular sciences · 2026Review
- Characterization and mechanistic regulation of the Bovine inflammasome.Veterinary research communications · 2026Article
- Potential Role of Inflammasomes in Aging.International journal of molecular sciences · 2025Review
- Article
- Divergent functions of NLRP3 inflammasomes in cancer: a review.Cell communication and signaling : CCS · 2023Review
- JC2-11, a benzylideneacetophenone derivative, attenuates inflammasome activation.Scientific reports · 2022Article
- Serum plays an important role in reprogramming the seasonal transcriptional profile of brown bear adipocytes.iScience · 2022Article
- Analysis of necroptosis and its association with pyroptosis in organ damage in experimental pulmonary arterial hypertension.Journal of cellular and molecular medicine · 2022Article
- Korean Red Ginseng, a regulator of NLRP3 inflammasome, in the COVID-19 pandemic.Journal of ginseng research · 2022Review
- Article
- NLRP3 Triggers Attenuate Lipocalin-2 Expression Independent with Inflammasome Activation.Cells · 2021Article
- Ameliorative effects of Schisandrin B on Schistosoma mansoni-induced hepatic fibrosis in vivo.PLoS neglected tropical diseases · 2021Article
- Korean Red Ginseng attenuates ultraviolet-mediated inflammasome activation in keratinocytes.Journal of ginseng research · 2021Article
- Riboflavin, vitamin B2, attenuates NLRP3, NLRC4, AIM2, and non-canonical inflammasomes by the inhibition of caspase-1 activity.Scientific reports · 2020Article
- NLRP3 inflammasome: a new therapeutic target for high-risk reproductive disorders?Chinese medical journal · 2020Article
- Fructose-arginine, a non-saponin molecule of Korean Red Ginseng, attenuates AIM2 inflammasome activation.Journal of ginseng research · 2020Review
- Characterization of equine inflammasomes and their regulation.Veterinary research communications · 2020Article
- Pre-evaluation of humoral immune response of Bactrian camels by the quantification of Th2 cytokines using real-time PCR.Journal of biomedical research · 2020Article
- Organosulfur Compounds: A Review of Their Anti-inflammatory Effects in Human Health.Frontiers in nutrition · 2020Review
- In vitro expression of NLRP inflammasome-induced active Caspase-1 expression in normal human epidermal keratinocytes (NHEK) by various exogenous threats and subsequent inhibition by naturally derived ingredient blends.Journal of inflammation research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory responses are essential in eliminating harmful substrates from damaged tissue and inducing recovery. Several cytokines participate in and facilitate this response. Certain cytokines such as interleukin (IL)-1β and IL-18 are initially produced in precursor form in response to toll-like receptor (TLR) ligands and undergo maturation by inflammasomes, which are cytosolic multi-protein complexes containing nucleotide-binding oligomerization domain (NOD)-containing protein 2-like receptors (NLRs). Immune modulators targeting inflammasomes have been investigated to control inflammatory diseases such as metabolic syndrome. However, most immune modulators possessing anti-inflammasome properties attenuate production of other cytokines, which are essential for host defense. In this review, we analyzed the effect of anti-inflammasome agents on the production of cytokines which are not regulated by inflammasome and involving in initial immune responses. As a result, the inflammasome inhibitors are put into three categories: non-effector, stimulator, or inhibitor of cytokine production. Even the stimulator of cytokine production ameliorated symptoms resulting from inflammasome activation in mouse models. Thus, we suggest ideal immune modulators targeting inflammasomes in order to enhance cytokine production while inhibiting cytokine maturation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.